Xylem XYL
Industrials · Industrial - Machinery · Synthos Deep Dive · 2026-07-03
The Overview
Xylem makes the pumps, meters, pipes, filters and software that move, measure and clean the world's water — the unglamorous plumbing behind city water utilities, factories and buildings. It is a good, steady business: it sells things the world always needs, it doesn't carry much debt, and its profits are slowly getting fatter.
The catch is the price and the chart. You're paying about 29 dollars for every 1 dollar of last year's profit — a premium — for a company whose sales only grow about 5% a year. And the stock has actually fallen about 10% over the past year while the overall market rose ~21%, and it's trading below its longer-term trend line. So you'd be paying up for slow growth in a stock that's currently sliding.
Our verdict is Watch — a fine company, but not at this price and not with the chart pointing down. Wait for it to get cheaper or for the trend to turn.
Here's what our three scores mean in everyday terms:
- Downside Risk 4/10 (fairly safe, but not cheap). Low debt and a stable business cushion the downside, but the rich price and falling chart add risk.
- Growth Quality 6/10 (solid, not spectacular). Reliable, improving profitability — but the growth is modest and returns on capital are only okay.
- Exponential Potential 3/10 (low). This is a slow-and-steady utility-like grower, not a rocket. Don't expect it to double quickly.
The one big worry: you overpay today for slow growth, and the stock keeps drifting lower until the valuation catches up with reality.
Putting a number on it: our fair-value estimate is $122 against a current price of $111.31 — real upside if our numbers are right.
Our summary metrics
Low leverage (0.7× net-debt/EBITDA) & beta 1.04, but 29× trailing EPS on ~5% organic growth and a downtrend below the 200-DMA.
~12% forward adj-EPS CAGR, EBITDA margin expanding to ~23%, but low-teens ROE/ROIC and only mid-single-digit organic revenue.
A defensive water compounder, not an exponential — mid-single-digit organic growth, decelerating, no acceleration to compound.
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Exponential Potential
A defensive water compounder, not an exponential — mid-single-digit organic growth, decelerating, no acceleration to compound.
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $150 (high $161 / low $133; 19 Buy · 20 Hold · 1 Sell = Hold) — context, not our anchor |
| Valuation | 29× trailing EPS · ~21× FY26E adj · ~19× FY27E adj · EV/S 3.2× · EV/EBITDA 16.3× |
| Technicals | Downtrend — $118, −23% off 52-wk high, below the 200-DMA, RSI 75 (overbought), −10% 12-mo (SPY +21%) |
| Conviction | Low — 0 expert voices, 0 claims in the Synthos KB; call rests entirely on fundamentals + quant |
| Position sizing | If owned: small defensive sleeve, ≤2%; most investors can wait for a better entry |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for XYL — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $111.31, 6% below the 50-day average ($118), 11% below the 200-day average ($125) — a downtrend. 27% below the 52-week high of $153, 5% above the 52-week low of $106.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $111.31 is currently inside the band (band $110–$125).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 37.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently below its signal line by 0.79, negative momentum.
Relative performance vs S&P 500 & its sector (XLI (sector)), set to 100 a year ago
Solid = XYL · dashed = S&P 500 · dotted = XLI (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. What it is
Xylem Inc. (NYSE: XYL) is a ~$28B-market-cap global water-technology company spun out of ITT in 2011 and headquartered in Washington, DC. It designs, makes and services the engineered products that move, treat, measure and manage water for utilities, industrial customers, and residential/commercial buildings worldwide — pumps and controls (Flygt, Godwin, Bell & Gossett, Goulds), treatment and disinfection (Wedeco, Leopold, Sanitaire), and smart metering / analytics (Sensus, YSI, Xylem Vue). It employs ~22,000 people. Fiscal year ends December 31. CEO: Matthew Pine.
The investment identity is "secular water": aging infrastructure, water scarcity, tightening regulation and utility digitization are long-duration demand tailwinds — Xylem is one of the cleanest large-cap ways to own that theme.
Revenue mix (FY2025, from filings):
- By segment (FMP product segmentation): Water Infrastructure $2.64B · Measurement & Control Solutions $2.09B · Applied Water $1.85B. (Note: the FMP FY25 product breakout does not restate the Water Solutions & Services segment shown in FY24 (~$2.34B); Xylem reorganized reporting after the 2023 Evoqua acquisition, so segment lines are not clean year-over-year. Total FY25 revenue is $9.035B.)
- By geography: United States $5.21B (58%) · Europe $1.84B (20%) · Asia Pacific $1.22B (14%) · other $0.77B (8%). US-weighted but genuinely global.
The defining recent event is the 2023 Evoqua merger (~$7.5B), which nearly doubled revenue (FY22 $5.5B → FY23 $7.4B → FY25 $9.0B), added recurring water-services revenue, and drove the goodwill on the balance sheet to $8.3B. Most of the reported revenue growth since 2022 is that acquisition; underlying organic growth is mid-single-digit (Q1'26 orders and revenue were flat organically per management).
2. The expert thesis — why the panel is bullish (traceable)
There is no expert thesis to report. The Synthos knowledge base contains ZERO claims on XYL (total_claims: 0, net_bullish_voices: 0). No net-bullish voice and no cautionary voice in our tracked expert panel currently covers Xylem.
This matters for how you read the rest of the note: the verdict here is entirely fundamentals- and quant-driven. There is no independent expert conviction — bullish or bearish — to lean on, and per the Synthos house standard we will not manufacture any. Where LLY earns a "Core" conviction rating from 13 reconciled expert voices, XYL earns none, and its low conviction rating reflects exactly that absence of edge, not a negative expert signal.
If and when tracked experts begin covering the name, this section will be populated with real, reconciled claim_ids. Until then: treat this as a screen-and-model call, not a high-conviction one.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
| Score | 0–10 | The read |
|---|---|---|
| Downside Risk (lower = safer) | 4 · Low-Moderate | Balance sheet is a genuine strength — net-debt/EBITDA 0.7×, interest coverage ~49×, beta 1.04, defensive end markets. But 29× trailing EPS on ~5% organic growth, and a chart in a downtrend below the 200-DMA, add valuation/momentum risk. |
| Growth Quality | 6 · Solid | ~12% forward adj-EPS CAGR (FY26E→FY29E), adj-EBITDA margin expanding to ~23%, durable moat and recurring water-services revenue — but ROE ~8.7% / ROIC ~6.7% are only okay, and organic revenue is mid-single-digit. |
| Exponential Potential | 3 · Low | Defensive water compounder. Revenue growth is decelerating toward mid-single-digit organic; EPS growth is margin-led, not volume-led. No acceleration, so nothing to compound exponentially. A great business — but not an exponential one. |
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. (EPS below is on the Street's adjusted basis, which runs well above GAAP — FY25 GAAP EPS was $3.93 vs ~$5.05 adjusted.)
| Case | Key assumptions | Fair value |
|---|---|---|
| Bull | Organic growth re-accelerates to mid/high-single-digit; margin transformation delivers the high end (~23.3%+ adj EBITDA); FY27E adj EPS beats to ~$6.40; market pays a premium ~24× for water quality. | ~$154 (+30%) |
| Base (our anchor) | Estimates roughly hit — FY27E adj EPS ~$6.09; a low-teens-EPS-growth defensive compounder earns a ~20× forward multiple. | ~$122 (+3%) |
| Bear | Organic demand stays flat/soft (as in Q1'26), margin gains stall, a cyclical industrial slowdown bites; FY27E adj EPS ~$5.50; multiple de-rates to ~15× as the market re-rates a slow grower. | ~$83 (−30%) |
Synthos fair value = the base case, ~$122 (+3%), with the full $83–$154 span as the honest range. Note our base sits well below the Street's $150 consensus: the sell-side is effectively underwriting the bull-case multiple (~24×+ forward) on a mid-single-digit organic grower, and we think that is optimistic given the broken chart and flat Q1'26 organics. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). XYL is a defensive compounder with low exponential potential:
- Forward growth: revenue CAGR FY25→FY29E ~4.3% ($9.0B → $10.7B); adjusted-EPS CAGR ~12% ($5.54 FY26E → $7.78 FY29E) — and note the EPS growth is margin-led, not volume-led. That is a quality signal but a ceiling on the growth rate.
- Acceleration (the 2nd derivative) is negative: most of the 2022→2025 revenue jump was the Evoqua acquisition, not organic momentum. Underlying organic orders and revenue were flat in Q1'26 on management's own numbers. There is no organic acceleration to compound — the opposite of what an exponential needs.
- Room to run: the water-infrastructure TAM is genuinely large and long-duration (aging pipes, PFAS remediation, utility digitization), so this is not a saturated market. But at $28B market cap and a mid-single-digit organic grower, "room to run" translates into steady compounding, not a multibagger. A 3× from here would require either a much faster organic rate or serial large acquisitions.
- Reinvestment runway: moderate capex (~$331M/yr, ~3.7% of revenue) and bolt-on M&A; FCF ~$910M FY25. Reinvestment is disciplined but not the kind of aggressive, high-ROIC redeployment that drives exponential outcomes.
Exponential Potential: Low (3/10). Own XYL — if at all — as a defensive, secular-water compounder for the long haul, explicitly not for a fast multibagger. It is a good business that scores low here precisely because it is steady, not accelerating.
5. Financials (real numbers — FMP annual/quarterly)
- Revenue: FY25 $9.035B, +5.5% (FY24 $8.56B; FY23 $7.36B; FY22 $5.52B). The big FY22→FY23 step is the Evoqua deal; underlying organic growth is mid-single-digit and was flat in Q1'26.
- Quarterly trajectory: Q1'25 $2.07B → Q2 $2.30B → Q3 $2.27B → Q4 $2.40B → Q1'26 $2.125B (+2.7% YoY reported, flat organic). Steady, not accelerating.
- Margins: gross 38.6% TTM, adj-EBITDA ~20.6% Q1'26 (guided to 22.9–23.3% FY26), net 10.7% TTM. The multi-year margin-expansion program is the real earnings driver.
- Earnings: GAAP net income $957M FY25 (EPS $3.93); adjusted EPS ~$5.05. Q1'26 GAAP EPS $0.79 / adjusted $1.12 (+9%).
- Cash flow: operating CF ~$1.24B, capex ~−$331M, FCF ~$910M FY25 (FCF margin ~10%, guided 10.2–11.0% FY26). Solid cash conversion.
- Balance sheet: total debt $2.06B, cash $1.48B, net debt just $584M → net-debt/EBITDA ~0.7× (down from ~2.0× at the Evoqua close). Investment-grade, comfortably financed. Goodwill + intangibles are $10.6B (~60% of assets) — a legacy of the Evoqua deal and an impairment watch-item if growth disappoints.
6. Valuation — priced in or room?
XYL is not cheap. Trailing 29× GAAP EPS, 3.2× EV/sales, 16.3× EV/EBITDA, ~29× P/FCF. On the Street's adjusted basis the forward multiple is ~21× FY26E → ~19× FY27E → ~15× FY29E — the multiple compresses if the margin program delivers, but the starting multiple already prices in a lot of that success for a company growing organic revenue at ~5% and adj EPS at ~12%. The PEG (~2.9 forward) is elevated. The dividend yield is modest (~1.4%, payout ~41%).
The bull case rests on "pay up for scarce, defensive, secular-water quality" — a valid framing that has historically kept water names at a premium. But the honest read is that the Street's $150 target embeds ~24×+ forward earnings, i.e. the bull-case multiple, on a name whose chart is broken and whose organic growth is currently flat. Our base-case ~$122 gives XYL a still-premium ~20× forward — fair for the quality, not generous. Street targets (context): consensus $150, high $161, low $133 — we sit below the Street because we are unwilling to underwrite a re-rating on top of decelerating organics. Not a value buy; a quality-at-a-full-price name best bought lower.
7. Technicals (from the tech block)
- Trend: down. $118.12 sits above the 50-DMA ($112.88) but well below the 200-DMA ($130.84) — a classic downtrend / death-cross posture. MACD is mildly positive (+1.53) off the recent bounce, but the primary trend is lower.
- Location: −22.8% off the 52-week high ($152.95), only +11% off the 52-week low ($106.34) — near the low end of its range, and the max drawdown from peak is the full −22.8%.
- Momentum: RSI(14) 74.8 — overbought (>70). The recent bounce is stretched short-term, so this is a poor entry point on momentum grounds.
- Relative strength (the tell): XYL −9.8% 12-mo vs SPY +20.6% and QQQ +30.3%; −3.6% 3-mo vs SPY +13.7%. Persistent, material underperformance of both the market and the Nasdaq — the opposite of a leadership name.
- Read: technicals do not confirm a buy. Below the 200-DMA, overbought on a bounce, and lagging the market badly. If anything, they argue for patience — wait for either a reclaim of the 200-DMA on volume or a pullback that resets RSI before considering an entry.
8. Moat & competitive position
Xylem's moat is install-base and specification-driven: decades-old pump and treatment brands (Flygt, Godwin, Wedeco, Bell & Gossett) that are spec'd into utility and municipal systems with long replacement cycles, high switching costs, and a growing tail of recurring aftermarket, services and metering-network revenue (bolstered by Evoqua and Sensus). Regulation (water quality, PFAS), aging infrastructure and utility digitization are durable tailwinds. It is a scale leader in a fragmented, defensive category. The limits: end demand is tied to municipal budgets and industrial capex (some cyclicality), and the metering/analytics side competes with larger diversified industrials.
Peer set (market cap): the closest water/flow comps are Pentair $12.4B, A. O. Smith $8.8B, IDEX $16.6B, Franklin Electric $4.6B, Flowserve $9.2B, Dover $28.8B, ITT $16.7B (Xylem's former parent), Ingersoll Rand $31.5B, Graco $12.5B; larger diversified industrials Emerson $77.9B, Eaton $154.7B, Parker-Hannifin $121.4B, Illinois Tool Works $78.5B. Xylem is the largest pure-play water name in the group and typically carries a premium multiple for that purity — the key debate is whether ~5% organic growth justifies it.
9. Management, capital allocation & guidance
- Capital allocation: disciplined — organic capex ~$331M/yr, bolt-on M&A (~$200M FY25), a growing dividend ($1.66/yr, ~41% payout, ~1.4% yield) and modest buybacks, all while deleveraging post-Evoqua to 0.7× net-debt/EBITDA. Sensible for a defensive compounder; the big swing factor is whether the "multi-year operating transformation" (management's phrase) keeps expanding margins.
- Insider activity: the recent Form 3/4 filings (2026-07-01, EVP Joseph Johnston; director Uday Yadav's May award) are routine onboarding grants and option holdings, not open-market discretionary selling — no alarming signal in the sampled window.
- Management's own guidance (the earnings-release track — half-weighted, self-interested by design): the SEC 8-K (Q1'26 release, filed 2026-04-28) carries real forward guidance. Management now guides FY2026 revenue ~$9.2–9.3B (up ~2–3% reported / 2–4% organic), adjusted EBITDA margin ~22.9–23.3% (up 70–110 bps), adjusted EPS $5.35–5.60, and free-cash-flow margin ~10.2–11.0%. This is genuine, specific guidance — we give it half weight as management talking its own book, but it is consistent with the analyst estimates our model uses, and the margin-expansion story is the core of the bull case. The Street FY26E adj EPS ($5.54) sits mid-range of guidance.
10. Catalysts & what to watch
- Next earnings: 2026-07-30 (Q2'26; Street EPS $1.34, revenue ~$2.35B). The key lines: organic order and revenue growth (does it turn positive off Q1'26's flat print?) and adjusted-EBITDA margin progress toward the 22.9–23.3% guide.
- Organic growth inflection: the whole "compounder" case needs organic revenue to move above mid-single-digit; flat organics are the bear's evidence.
- Margin transformation: delivery of the multi-year operating-transformation savings is the primary EPS driver.
- 200-DMA reclaim: a technical turn (reclaiming ~$131 on volume) would materially improve the entry.
- M&A: further bolt-ons or a larger deal — capital-allocation discipline and integration risk both in play.
Thesis tripwires (what would change the call): two consecutive quarters of negative organic growth (bear confirmation) → toward Avoid; conversely, organic re-acceleration to mid/high-single-digit plus a 200-DMA reclaim plus a pullback in valuation → toward Buy — Tactical.
11. Key risks
- Valuation / no margin of safety: ~29× trailing EPS (~21× forward adj) on ~5% organic growth leaves little room for a stumble; a de-rate to a market multiple is a real downside path (see bear case).
- Broken technicals: below the 200-DMA, overbought on a bounce, −10% 12-mo vs a +21% market — momentum is against you.
- Cyclicality / demand: municipal budgets and industrial capex can soften; Q1'26 organic growth was already flat. Management's own forward-looking-statements flag industrial/economic conditions, tariffs and FX.
- Goodwill/intangibles: $10.6B (~60% of assets) from Evoqua — impairment risk if growth or margins disappoint.
- No expert edge: zero KB coverage means no independent conviction to corroborate (or challenge) the quant/fundamental read — this is a lower-confidence call by construction.
12. Verdict, position sizing & monitoring
Watch. Xylem is a genuinely good, defensive, secular-water business — clean balance sheet (0.7× net-debt/EBITDA), expanding margins toward ~23%, durable install-base moat, disciplined capital allocation. But three things keep it off the buy list today: (1) valuation — ~29× trailing / ~21× forward adj on only ~5% organic growth; (2) technicals — a downtrend below the 200-DMA, overbought on a bounce, badly lagging the market; and (3) no expert edge — zero Synthos KB coverage, so the call rests on fundamentals and quant alone. Our base-case fair value (~$122) sits below the Street's $150, because we won't underwrite a re-rating on decelerating organics.
- Sizing: if you already own it as a defensive water holding, a small (≤2%) position is defensible; most investors are better served waiting for a cheaper entry or a confirmed trend turn.
- Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print. Would move to Buy — Tactical on organic re-acceleration + a 200-DMA reclaim + a better price. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $118.12.
- Single biggest risk: overpaying today for slow growth and watching the stock drift lower until the multiple normalizes.
Provenance & disclosures
- Traceability: 0 KB claims, breadth 0 — there is no expert coverage of XYL in the Synthos knowledge base, and none is fabricated. This note is explicitly fundamentals- and quant-driven; conviction rating is Low by construction.
- Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · no expert claims. Forward figures are analyst consensus (FMP) or management guidance, labeled as estimates. Adjusted EPS runs materially above GAAP (FY25 GAAP $3.93 vs ~$5.05 adjusted) — forward multiples use the adjusted basis the Street quotes.
- Management caveat: the FY26 guidance in §9 is management's own book, half-weighted by design; sourced from the SEC 8-K Item 2.02 earnings release (filed 2026-04-28).
- Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
- Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").